Welcome to the first ever MicroCapClub Invitational where our membership is showcasing several companies we are discussing in our members forum. The government is mandating the switch to electronic health records (EHR) over the next few years, which is also propelling physician’s use of e-prescriptions. E-prescriptions are expected to grow from 570 million in 2011 to 2 billion by 2016. So who is the microcap benefactor of this trend? Enter, OptimizeRx (OPRX) and their SampleMD e- coupon software that is currently embedded in over 300 EHR’s/e-prescribe software providers including the largest ones such as Allscripts (MDRX), NewCrop, and Dr. First. OptimizeRX gets paid $4-5 each e-coupon distribution. The operating leverage in the business is quite extraordinary as more and more pharmaceutical companies partner with SampleMD for e-coupons. Listen to Chairman and Founder Dave Harrell and CEO David Lester as they tell the story.

1. Optimizerx Corporation
OTCBB:OPRX
OPTIMIZERx Corporation
400 Water Street, Suite 200
Rochester, MI 48307
Phone: 248.651.6568
Fax: 248.453.5529
http://www.optimizerxcorp.com/

2. SAFE HARBOR :
This presentation contains forward-looking statements within the definition of
Section 27A of the Securities Act of 1933, as amended and such section 21E of the
Securities Act of 1934, amended. These forward-looking statements should not be
used to make an investment decision.
The words 'estimate,' 'possible' and 'seeking' and similar expressions identify
forward-looking statements, which speak only as to the date the statement was
made. The company undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information, future events,
or otherwise.
Forward-looking statements are inherently subject to risks and uncertainties, some
of which cannot be predicted, or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or underlying the
forward-looking statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect of government
regulation, competition and other material risks.

3. What's Changing in the Drug Industry?
“Pharma Reps & Samples Decline In Size, Effectiveness, and ROI”
Sales Rep Attrition Visits With Samples (Millions)
105,000 120
110
90,000 100
90
75,000 80
70
60,000 60
2003 2007 2009 2012 2007 2008 2009 2010 2011
? Did You Know…
Source:
2. Cegedim Strategic Data
According to the spring 2011 Access Monitor™ report, https://www.cegedimstrategicdata.com/
only 54% of prescribers were “rep-accessible”?

4. Patient Cost’s is also impacting Pharmaceutical
Promotion as the rise in co-pay costs is now a barrier
Co-pay Amount
• First, measures for Tier 4
Specialty Drugs
improving adherence must $50
address financial barriers … Tier 3
Other Covered Brand Drugs
• Especially the co-payments $40
that patients must make for Tier 2
medications.” Preferred Brand Drugs
$25
• Patients Are Resisting Tier 1
Increases In Co-pay Costs, Covered Generic Drugs $5
which in turn is affecting Fill
Rates/Adherence Source:
3. New England Journal of Medicine
https://www.nejm.org/

5. Key Trends—Trial Vouchers & Coupons Drive Adherence!
Co-Pay Cards And Coupons: Letting The Facts Get In The Way
Impact Of Co-Pay Offset Program On Patient
+20 Days–
Adherence to BRAND Increased Loyalty:
270 275 Longer Therapy
Than Cohort At
+20 DAYS Equivalent Co-Pay
250 250
+40 Days–
+40 DAYS
225 Response To Lower
210 Co-pay:
More Days Of
200 Therapy Based On
Initial Co-Pay Level
175
Sources:
6. Wolters Kluwer Health (PTD search)
$25 ECP Co-Pay $25 Co-Pay $50 Co-Pay http://www.wolterskluwerhealth.com/
$60 Co-Pay Control Group 2: Control Group 2:
reduced to $25 Paying $25 Paying $60
w/Co-pay Card w/Co-pay Card w/Co-pay Card 7. Pharmaceutical
Care Management Association
http://www.amundsengroup.com/
Effect Of Moving Patient From $60 to $35 Co-pay

6. Trial Vouchers & Coupons Are Now Replacing Samples
Industry report conservatively made the following assumptions:
• Nearly all manufacturers offer co- • There were 100M in prescriptions
payments not based on income associated with coupons in 2010 or
11% of brand prescriptions
• In July 2011 there were 310 co-pay card
programs in the US, a 260% increase • Co-pay coupons to increase 15% per
from 2009 year from 100M in 2010 to 500M in
2021
• Co-pay cards were 1/3 of overall
prescription drug market and 13% of • Co-pay coupons will represent 20%
branded drugs of non-specialty brand prescriptions
in 2014, 30% in 2017, and 50% in
• The $4B Samples Market is going digital 2021
which by way of efficiencies should
Improve Adherence
Source:
4. Cleveland Resource Company Source:
5. Pharmaceutical Care Management Association
http://pcmanet.org/
http://pcmanet.org/

7. Market Size— Physicians Practice Flow is now Electronic!
eprescribing to grow by 600% in five years.
?
Did You Know…
• 570M prescriptions were routed electronically in 2011?
• More than 1 in 2 office-based physicians will be e-prescribed
in 2011?

8. SampleMD is partnering with the largest
‘ePrescribing’ and electronic healthcare record (EHR)
software platforms to reach more targeted care
providers who are active electronic prescribers
Allscripts has 70,000 active Physicians ePrescribe users

9. SampleMD: How it works
SampleMD is a software application that replaces drug samples by allowing
doctors to automatically add sponsored drug trial vouchers & co-pay discount
coupons from their desktops and ePrescribing system.
SampleMD resides within our software partners ePrescribe or electronic
health record (EHR) software offerings.
SampleMD is already installed in Allscripts Inc. (NASDAQ:MDRX), New Crop
and Dr. First, which enables SampleMD to reside in over 300 individual EHR
systems.
Doctors are able to offer patients sample vouchers or coupons right within
their prescribing work flow automation, making it easy and simple to use.
Coupon info is automatically sent to pharmacy with eRx
SampleMD is paid $4-$5 by the manufacturer each time an ecoupon or
evoucher is distributed to a patient.

10. SampleMD provides Clear Solutions:
SampleMD enables branded drug manufacturers
access to providers with out sales personnel, along
with access to their patients via a very cost effective
way to get their cost saving offers directly to
patients.
SampleMD, by partnering with other software
partners, is able to be within the primary workflow
of hundred’s of thousands of healthcare providers.
SampleMD in turn shares revenue with each
software partner that provides them direct access to
health care providers.

11. SampleMD™ Promotional Technology
Each Platform Offers A Cost-Effective Solution
OptimizeRx website—industry standard,
rules-based, and embedded functionality
• eCouponing: eVouchers and
eCoupons generated from the
EMR/ePrescribe System
• Patient Education: Access Patient
Education and Adherence Programs at
the point of prescribing
• Product Info & Support: Access
product information and live support
from the EMR/ePrescribe System
• Rep Visit: Health providers can
request a Rep Visit and appointment
time

12. SampleMD™ Promotional Technology
Promotion to Doctors at Most Critical Time: Point of Prescribe!
Once product is selected, SampleMD
proprietary rules based engine
determines eligible product support
Doctor searches for
drug to ePrescribe
Option to send to patient
mobile & email
Upon doctor sending the
ePrescription, your eCoupon
& Patient Ed. is auto
displayed & printed for
patient and coupon info is
included right within eRx to
pharmacist!

14. Our Key Health Systems & EHR/ ePrescribe Platform Partners

15. Key Health Pharmaceutical & Health Care Clients
“Building the premier digital path to deliver direct
support from leading Pharma Companies”

16. SampleMD Revenue Metrics: “Highly Leveraged”
Set Up Fee:
$25K
Reporting:
$1K/mth.
Cost Per Coupon
Distribution:
NOTE: We do have Enterprise
$5.00
Wide discounts to promote
Manufacturers to add portfolio
of products to drive increased volume

17. SampleMD Actual Usage Metrics July 2011-July2012

18. OPRX FISCAL PERFORMANCE Q3 2011 v. Q3 2012
Fiscal period Revenue for period 9 Mos Q3 loss 9 mos total
REVENUE loss
2011 Q3 $191,593 $785,610 ($1,087,504) ($2,027,619)
2012 Q3 $453,154 $1,297,980 ($106,174)* ($482,969)
* The Company broke even on a cash basis prior to non-cash charges in Q3 2012

19. Thank you for your interest in OPRX
Key Stock Data: Equivalents: Financial Summary
Recent Price( 12/4/12): 14m warrants are Total assets $2.4m a/o
$1.05 outstanding at $2-3 strike 6/30/12
price.
52 Week range: $0.53-$1.97 Management holds certain Liabilities: $1.1 a/o 6/30/12
option agreement’s mostly trade payables
MKT CAP: $20.1m primary
only
Ave Volume: 34,000 Fully diluted share count w
(trailing3 mos.) equivalents: 34m.
Company: Mr. Dave Harrell, Chairman IR Contact : Mr. Craig Stewart
248.651.6568 office 585-737-9966 cell
dharrell@samplemd.com cstewart@ncainc.com